Royal Bank of Canada reaffirmed their outperform rating on shares of Illumina (NASDAQ:ILMN – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $258.00 target price on the life sciences company’s stock.
Other research analysts also recently issued research reports about the stock. Citigroup upgraded shares of Illumina from a sell rating to a neutral rating and boosted their price target for the stock from $85.00 to $120.00 in a research report on Monday, December 11th. Stephens began coverage on shares of Illumina in a research report on Thursday, December 14th. They issued an overweight rating and a $170.00 price target on the stock. TD Cowen downgraded shares of Illumina from an outperform rating to a market perform rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Bank of America downgraded shares of Illumina from a neutral rating to an underperform rating and dropped their price target for the stock from $140.00 to $100.00 in a research report on Tuesday, December 12th. Finally, Scotiabank upgraded shares of Illumina from a sector perform rating to a sector outperform rating and set a $185.00 price target on the stock in a research report on Monday, December 18th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of Hold and a consensus target price of $166.95.
Illumina Trading Up 1.5 %
Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm posted $0.14 EPS. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts predict that Illumina will post 1.03 earnings per share for the current year.
Institutional Trading of Illumina
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Illumina by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares in the last quarter. Polen Capital Management LLC grew its stake in shares of Illumina by 0.6% in the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after acquiring an additional 29,153 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Illumina by 5.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock worth $550,212,000 after acquiring an additional 208,267 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Illumina by 6.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock worth $500,926,000 after acquiring an additional 225,074 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Illumina by 18.6% in the 2nd quarter. Geode Capital Management LLC now owns 3,473,112 shares of the life sciences company’s stock worth $649,525,000 after acquiring an additional 544,786 shares in the last quarter. Institutional investors own 92.17% of the company’s stock.
Illumina Company Profile
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- Five stocks we like better than Illumina
- Dividend Payout Ratio Calculator
- 3 attractive stocks that insiders are buying
- How to Invest in the FAANG Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Are the FAANG Stocks and Are They Good Investments?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.